BioSpace News Archive

Candel Therapeutics, Inc. announced that, in the second quarter of 2024, it expects to report topline overall survival data from its ongoing, open-label, phase 2 clinical trial of CAN-2409 plus valacyclovir in combination with continued immune checkpoint inhibitor treatment in patients with non-resectable, stage III/IV non-small cell lung cancer who progressed while on treatment with PD-1 inhibitor therapy.

Avanos Medical, Inc. announced that it will host an Investor Day at Convene on 101 Park Avenue, New York, on Tuesday, June 20th, 2023.

W. L. Gore & Associates announced the initiation of the Gore VBX FORWARD Clinical Study to compare the VBX Stent Graft to bare metal stenting for patients with complex iliac occlusive disease.

Kyowa Kirin, Inc., an affiliate of Kyowa Kirin Co., Ltd., a global specialty pharmaceutical company, announced an initiative, Proactively Recognizing Occurrence in Blood through Education housed on PROBEinCTCL.com which was developed to educate HCPs on the importance of assessing blood involvement in Sézary Syndrome and Mycosis Fungoides—two subtypes of cutaneous T-cell lymphoma.

Petauri Health, a New York–based, purpose-built pharmaceutical services platform, announced that it has acquired The Kinetix Group, also known as TKG.

DAMONA Pharmaceuticals announced the appointment of John Reilly as the company’s Chief Executive Officer and member of the Board of Directors.

NeuroBo Pharmaceuticals, Inc. announced that data on DA-1726, a novel oxyntomodulin analogue functioning as a glucagon-like peptide-1 receptor and glucagon receptor dual agonist, was accepted for one ePoster theater discussion and two general poster presentations at the American Diabetes Association 83rd Scientific Sessions, being held June 23-26, 2023 at the San Diego Convention Center in San Diego, CA and virtually.

Reflow Medical, Inc. announced the six-month results of the DEEPER OUS clinical trial evaluating the safety and efficacy of the Bare Temporary Spur Stent System.

MEI Pharma, Inc. announced that, consistent with the Company’s succession planning, Brian Drazba’s tenure as Chief Financial Officer of the Company will end no later than September 1, 2023, and the Company has hired Justin File as his successor.

Viridian Therapeutics, Inc. announced that multiple abstracts featuring data on the Company’s lead investigational therapy for the treatment of thyroid eye disease will be presented at the Annual Meeting of the Endocrine Society to be held June 15-18, 2023, in Chicago, Illinois.